Date: 2017-01-06
Type of information: Nomination
Compound:
Company: Neurocrine Biosciences (USA - CA)
Therapeutic area: Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 6, 2017, Neurocrine Biosciences announced that David-Alexandre "DA" Gros has joined the executive management team as President and Chief Operating Officer. Dr. Gros joins Neurocrine from Alnylam Pharmaceuticals where he served as Senior Vice President, Chief Business Officer and was a member of the Management Board. His responsibilities included strategy, finance, business development, communications, investor relations, and shared services. Prior to Alnylam, as Executive Vice President and Chief Strategy Officer at Sanofi, where he was a member of the Executive Committee, Dr. Gros' responsibilities included corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments, including the corporate venture fund which he re-launched. Before Sanofi, Dr. Gros held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. Dr. Gros holds an M.D. from The Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School, and a B.A. from Dartmouth College.
- Neurocrine also announced the grant of an inducement award to Dr. Gros pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. In connection with his employment by Neurocrine, Dr. Gros will be granted an inducement award consisting of a stock option to purchase 350,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of its grant date and the balance vesting each month over the remaining three years. This award is subject to the terms and conditions of Neurocrine's Inducement Plan. The award will be effective on February 1, 2017, which is the first day of the first calendar month following the commencement of Dr. Gros' employment with Neurocrine, and will have an exercise price equal to the closing price of Neurocrine's common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Dr. Gros' employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Financial terms:
Latest news:
Is general: Yes
